PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14

por Hultcrantz, M., Kleinman, D., Ghataorhe, P., Mckeown, A., He, W., Ling, T., Jewell, R. C., Byrne, J., Eliason, L., Scott, E., Opalinska, J.
Publicado 2022

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

por Malingré, M M, Beijnen, J H, Rosing, H, Koopman, F J, Jewell, R C, Paul, E M, Huinink, W W Ten Bokkel, Schellens, J H M
Publicado 2001

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY

por Suvannasankha, A., Bahlis, N., Trudel, S., Weisel, K., Koenecke, C., Oriol, A., Voorhees, P. M., Alonso, A. A., Callander, N. S., Mateos Manteca, M. V., Reddy, N., Hakim, S., Patel, N., Williams, D., Jewell, R. C., Zhou, X., Gupta, I., Nooka, A. K.
Publicado 2022